RxDoctor Payments Data

Joseph Andrews, MD

Dermatology · Dover, DENPI 1548321714

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,564 of the $1,936 with a category attached, or 80.8%. 16 manufacturers reported payments, led by Johnson & Johnson at 39.1% of the total. That places this record below the midpoint for dermatology clinicians in DE, where the typical reported total is $5,548.

$1,936in general payments, 2019–2025

Across 78 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$756
  • AbbVie$162
  • Novartis$160
  • Sanofi$150
  • Pfizer$138
  • Lilly USA, LLC$105
  • plus $464 from 10 others

What the payments were for

  • Food & beverage$1,56481%
  • Education$37119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,936 in reported general payments places this provider in the 30th percentile of 23 dermatology providers in Delaware.

See all dermatology providers in Delaware

Medicare billing

Part B allowed, 2024
$345,864
Medicare patients
1,054
Services billed
5,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$56,089
Triamcinolone Acetonide226$3,020
Fluorouracil46$2,924
Clobetasol Propionate43$2,080
Metronidazole28$1,379
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip55$1,300
Doxycycline Hyclate35$1,129
Mometasone Furoate68$1,026
Alclometasone Dipropionate38$1,025
Ketoconazole70$985
Betamethasone Dipropionate26$915
Selenium Sulfide61$705
Fluocinonide15$690
Fluocinolone Acetonide20$679
Ciclopirox14$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$60$56,08911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 23 dermatology providers in Delaware.

Other dermatology in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →